Non-randomized, multicenter, open, fixed-dose, single group, joint study to determine the efficacy and safety of Maoto for Influenza Type A

INTERVENTION: Test drug: Tsumura Mao‐to extract granule for prescription Normal adult dose is 7.5g p.o. in 2‐3 divided doses, before or between meals. Duration of administration: 5 days CONDITION: Influenza Type A PRIMARY OUTCOME: 1) Symptoms of Influenza; a.fever clearance time ; b.other symptoms (nasal discharge, nasal obstruction, sore throat, cough, muscle ache, arthralgia, lethargy or fatigue, headache); 2) Laboratory test for virus INCLUSION CRITERIA: 1) Patients with a fever >38.0C or >37.5C at the time of admission, or >38.0C within 4 hours of admission 2) Patients who tested positive on Rapid Influenza Type A Diagnostic Test 3) Patients with influenza symptoms within 48 hours of onset 4) Age: between 10 ‐ 65 y/o (at the time of acquisition of consent) 5) Gender: no specification 6) Consultation method: outpatient 7) Patients who can provide written informed consent ,if the patient is a minor, informed consent must be obtained from the patient and legal representative.